Marble Harbor Investment Counsel LLC boosted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,677 shares of the company’s stock after purchasing an additional 2,300 shares during the period. Johnson & Johnson makes up approximately 1.4% of Marble Harbor Investment Counsel LLC’s holdings, making the stock its 24th largest position. Marble Harbor Investment Counsel LLC’s holdings in Johnson & Johnson were worth $10,189,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth $35,000. Retirement Financial Solutions LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $40,000. TD Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $48,000. VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $52,000. Finally, Iron Horse Wealth Management LLC lifted its stake in Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
Johnson & Johnson Stock Down 1.4 %
JNJ stock opened at $154.41 on Friday. The firm has a market cap of $401.27 billion, a PE ratio of 32.30, a P/E/G ratio of 2.67 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The firm’s fifty day moving average is $159.89 and its 200 day moving average is $165.86. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business earned $2.67 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.08%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 99.58%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.